Skip to content

Study · Randomized controlled trial · 2005

5 results

A prospective randomized study for prevention of postrenal transplantation bone loss.

El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA

Kidney international1 May 2005Cited by 57 (Europe PMC)

PMID15840055 (opens in a new tab)DOI10.1111/j.1523-1755.2005.00306.x (opens in a new tab)PepBankPUB-15840055
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In renal transplant recipients, calcitonin increased lumbar spine BMD by 1.7%, while control BMD decreased by 3.2%.

    In plain wordsIn renal transplant recipients, lower spine bone density increased with calcitonin and decreased with control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 12 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD change
    1.7%
    group III (intranasal salmon calcitonin)
    Lumbar spine BMD change
    −3.2%
    control group IV

    Source sentences

    Summary
    BMD was increased at lumber spine by 2.1%, 0.8%, 1.7%, by 1.8%, 0.6%, 1.6% at femoral neck, and by 3.2%, 1.9%, 2.6% at forearm in groups I, II, and III, respectively, while it decreased by 3.2%, 3.8%, and 1.8% at the same sites, respectively, in control group (P= <0.05).
    3 context sentences
    Summary · context
    Sixty adult male recent renal transplant recipients were enrolled into the study.
    Summary · context
    Patients were randomized into 4 groups: group I received daily alfacalcidol 0.5 microg PO; group II received oral alendronate 5 mg/day; group III received intranasal salmon calcitonin 200 IU every other day; and group IV was considered a control group.
    Summary · context
    Every patient was supplemented with daily 500 mg oral calcium carbonate.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In renal transplant recipients, calcitonin increased femoral neck BMD by 1.6%, while control BMD decreased by 3.8%.

    In plain wordsIn renal transplant recipients, femoral neck bone density increased with calcitonin and decreased with control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseFemoral neck BMD
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 12 monthsAs given in this study (human).

    Measurements

    Femoral neck BMD change
    1.6%
    group III (intranasal salmon calcitonin)
    Femoral neck BMD change
    −3.8%
    control group IV

    Source sentences

    Summary
    BMD was increased at lumber spine by 2.1%, 0.8%, 1.7%, by 1.8%, 0.6%, 1.6% at femoral neck, and by 3.2%, 1.9%, 2.6% at forearm in groups I, II, and III, respectively, while it decreased by 3.2%, 3.8%, and 1.8% at the same sites, respectively, in control group (P= <0.05).
    3 context sentences
    Summary · context
    Sixty adult male recent renal transplant recipients were enrolled into the study.
    Summary · context
    Patients were randomized into 4 groups: group I received daily alfacalcidol 0.5 microg PO; group II received oral alendronate 5 mg/day; group III received intranasal salmon calcitonin 200 IU every other day; and group IV was considered a control group.
    Summary · context
    Every patient was supplemented with daily 500 mg oral calcium carbonate.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In renal transplant recipients, calcitonin increased forearm BMD by 2.6%, while control BMD decreased by 1.8%.

    In plain wordsIn renal transplant recipients, forearm bone density increased with calcitonin and decreased with control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseForearm BMD
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 12 monthsAs given in this study (human).

    Measurements

    Forearm BMD change
    2.6%
    group III (intranasal salmon calcitonin)
    Forearm BMD change
    −1.8%
    control group IV

    Source sentences

    Summary
    BMD was increased at lumber spine by 2.1%, 0.8%, 1.7%, by 1.8%, 0.6%, 1.6% at femoral neck, and by 3.2%, 1.9%, 2.6% at forearm in groups I, II, and III, respectively, while it decreased by 3.2%, 3.8%, and 1.8% at the same sites, respectively, in control group (P= <0.05).
    3 context sentences
    Summary · context
    Sixty adult male recent renal transplant recipients were enrolled into the study.
    Summary · context
    Patients were randomized into 4 groups: group I received daily alfacalcidol 0.5 microg PO; group II received oral alendronate 5 mg/day; group III received intranasal salmon calcitonin 200 IU every other day; and group IV was considered a control group.
    Summary · context
    Every patient was supplemented with daily 500 mg oral calcium carbonate.
  4. 04HumanNon-randomized trialEfficacy outcome

    In renal transplant recipients, iPTH decreased nonsignificantly in the calcitonin group.

    In plain wordsIn renal transplant recipients, parathyroid hormone did not decrease significantly with calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeiPTH
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU every other day · intranasal · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    iPTH level decreased significantly in group I, while the decrease was insignificant in other groups (P= 0.003).
    3 context sentences
    Summary · context
    Sixty adult male recent renal transplant recipients were enrolled into the study.
    Summary · context
    Patients were randomized into 4 groups: group I received daily alfacalcidol 0.5 microg PO; group II received oral alendronate 5 mg/day; group III received intranasal salmon calcitonin 200 IU every other day; and group IV was considered a control group.
    Summary · context
    Every patient was supplemented with daily 500 mg oral calcium carbonate.
  5. 05HumanNon-randomized trialSafety outcome

    In renal transplant recipients, transient hypocalcaemia occurred in 2 calcitonin-treated patients.

    In plain wordsIn renal transplant recipients, two calcitonin-treated patients had temporary low blood calcium.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableTransient hypocalcaemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    200 IU every other day · intranasal · 12 monthsAs given in this study (human).

    Measurements

    Patients with transient hypocalcaemia
    2 patients
    group III, intranasal salmon calcitonin

    Source sentences

    Summary
    Apart from transient hypocalcaemia in 3 patients in group II, and 2 patients in group III, no other significant adverse effects were noted.
    3 context sentences
    Summary · context
    Sixty adult male recent renal transplant recipients were enrolled into the study.
    Summary · context
    Patients were randomized into 4 groups: group I received daily alfacalcidol 0.5 microg PO; group II received oral alendronate 5 mg/day; group III received intranasal salmon calcitonin 200 IU every other day; and group IV was considered a control group.
    Summary · context
    Every patient was supplemented with daily 500 mg oral calcium carbonate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.